RecruitingNot Applicable

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

China150 participantsStarted 2019-02-21

Plain-language summary

This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.

Who can participate

Age range

12 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Positive hepatitis b surface antigen or hepatitis b virus DNA \> 0.5 year;
. Age from 12 to 65 years old;
. Serum total bilirubin level \> 10 times upper limit of normal;
. Prothrombin time activity \< 40% or prothrombin time international ratio \> 1.5；
. Do not receive nucleotide/nucleoside analogues treatment in the past half year.

Exclusion criteria

. Other active liver diseases;
. Hepatocellular carcinoma or other malignancy;
. Pregnancy or lactation;
. Human immunodeficiency virus infection or congenital immune deficiency diseases;
. Severe diabetes, autoimmune diseases;
. Other important organ dysfunctions;
. Using glucocorticoid;

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Survival rate in the follow-up

Timeframe: 144 week

Trial details

NCT IDNCT03920618

SponsorThird Affiliated Hospital, Sun Yat-Sen University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-31

Contact for this trial

Wenxiong Xu, Doctor

+8613760783281 xwx1983@163.com

View on ClinicalTrials.gov More Hepatitis B trials